September FDA news in review
Welcome to the first installment of "FDA News in Review," where each month we'll take a look at the agency's latest decision, approvals, warnings and recalls. We hope this feature will help you keep up on FDA trends--and catch up on stories you may have missed.
One of the top stories out of the FDA this month was the agency's push to fill 1,300 new positions. The new hires include chemists, biologists and microbiologists, many of whom will be assigned to the CDER. Overall, the agency is increasing its workforce by about 10 percent. And while the FDA was light on approvals this month, it was certainly busy monitoring drug safety. The agency announced that it will now release a quarterly list of drugs under investigation due to adverse events. The nature of the complaints will be included in the report, but the number of complaints won't be.
What's new at the FDA
FDA Approvals
FDA Decisions
Safety, Warnings & Recalls
Comments
By Mark Soufleris | Posted 3:36pm | October 4, 2008
Excellent idea. Great way to keep track of timely information in one spot.
Thank you.
By Anonymous | Posted 11:37am | October 6, 2008
any news on JnJ anti 10a Reva for fast track approval?
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
